Diagnosis of Prediabetes

Medical Clinics of North America

Volumn 95, Issue 2, 2011, Pages 341-352

  Shaw, Jonathan ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Diagnosis; Impaired fasting glucose; Impaired glucose tolerance; Prediabetes; Risk score

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

CARDIOVASCULAR DISEASE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; LIVER; MUSCLE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PREDIABETIC STATE; RISK ASSESSMENT; RISK FACTORS;

EID: 79251564939     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.11.012     Document Type: Review

References (42)

1. World Health Organization Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation 2006, World Health Organization, Geneva (Switzerland).
2. Tapp R.J., Dunstan D.W., Phillips P., et al. Association between impaired glucose metabolism and quality of life: results from the Australian diabetes obesity and lifestyle study. Diabetes Res Clin Pract 2006, 74(2):154-161.
3. Coutinho M., Gerstein H., Wang Y., et al. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
4. Barr E.L., Boyko E.J., Zimmet P.Z., et al. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 2009, 52(3):415-424.
5. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999, 354(9179):617-621.
6. Santaguida P.L., Balion C., Hunt D., et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ) 2005, 128:1-11.
7. Boyko E.J., Gerstein H.C., Mohan V., et al. Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabet Med 2010, 27:1226-1232.
8. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346(6):393-403.
9. Magliano D.J., Barr E.L., Zimmet P.Z., et al. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2008, 31(2):267-272.
10. Unwin N., Shaw J., Zimmet P., et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002, 19(9):708-723.
11. Shaw J., Zimmet P., Hodge A., et al. Impaired fasting glucose: how low should it go?. Diabetes Care 2000, 23:34-39.
12. Gabir M.M., Hanson R.L., Dabelea D., et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000, 23(8):1108-1112.
13. Hippisley-Cox J., Coupland C., Robson J., et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009, 338:b880.
14. Tabak A.G., Jokela M., Akbaraly T.N., et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009, 373(9682):2215-2221.
15. Brunner E.J., Shipley M.J., Witte D.R., et al. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006, 29(1):26-31.
16. Ford E.S., Zhao G., Li C. Prediabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010, 55(13):1310-1317.
17. Kim N.H., Pavkov M.E., Looker H.C., et al. Plasma glucose regulation and mortality in Pima Indians. Diabetes Care 2008, 31(3):488-492.
18. Qiao Q., Jousilahti P., Eriksson J., et al. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care 2003, 26(10):2910-2914.
19. Rijkelijkhuizen J.M., Nijpels G., Heine R.J., et al. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care 2007, 30(2):332-336.
20. Meigs J., Nathan D., D'Agostino R., et al. Fasting and postchallenge glycemia and cardiovascular disease risk. Diabetes Care 2002, 25(10):1845-1850.
21. Simmons R.K., Sharp S., Boekholdt S.M., et al. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events?. Arch Intern Med 2008, 168(11):1209-1216.
22. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979, 28:1039-1057.
23. American Diabetes Association Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
24. Charles M., Fontbonne A., Thibult N., et al. Risk factors for NIDDM in white population. Paris Prospective Study. Diabetes 1991, 40:796-799.
25. Brunzell J.D., Robertson R.P., Lerner R.L., et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976, 42(2):222-229.
26. Charles M., Balkau B., Vauzelle-Kervroedan F., et al. Revision of diagnostic criteria for diabetes. Lancet 1996, 348:1657-1658. [letter].
27. Genuth S., Alberti K.G., Bennett P., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26(11):3160-3167.
28. Godsland I.F., Jeffs J.A., Johnston D.G. Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 2004, 47(7):1157-1166.
29. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl 1):S62-S69.
30. International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32(7):1327-1334.
31. Mostafa S.A., Khunti K., Srinivasan B.T., et al. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Res Clin Pract 2010, 90(1):100-108.
32. Droumaguet C., Balkau B., Simon D., et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2006, 29(7):1619-1625.
33. Lindstrom J., Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003, 26(3):725-731.
34. Schwarz P.E., Li J., Lindstrom J., et al. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res 2009, 41(2):86-97.
35. Franciosi M., De Berardis G., Rossi M.C., et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care 2005, 28(5):1187-1194.
36. Silventoinen K., Pankow J., Lindstrom J., et al. The validity of the Finnish diabetes risk score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardiovasc Prev Rehabil 2005, 12(5):451-458.
37. Glumer C., Vistisen D., Borch-Johnsen K., et al. Risk scores for type 2 diabetes can be applied in some populations but not all. Diabetes Care 2006, 29(2):410-414.
38. Al-Lawati J.A., Tuomilehto J. Diabetes risk score in Oman: a tool to identify prevalent type 2 diabetes among Arabs of the Middle East. Diabetes Res Clin Pract 2007, 77(3):438-444.
39. Huxley R., Barzi F., Lee C.M., et al. Waist circumference thresholds provide an accurate and widely applicable method for the discrimination of diabetes. Diabetes Care 2007, 30(12):3116-3118.
40. Cameron A.J., Sicree R.A., Zimmet P.Z., et al. Cut-points for Waist Circumference in Europids and South Asians. Obesity (Silver Spring) 2010, 18(10):2039-2046.
41. Chen L., Tonkin A.M., Moon L., et al. Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart. Eur J Cardiovasc Prev Rehabil 2009, 16(5):562-570.
42. Chen L., Magliano D.J., Balkau B., et al. Maximising efficiency and cost-effectiveness of type 2 diabetes screening: the AusDiab study. Diabetic Medicine 2010, [Epub ahead of print].